AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02706288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss with very low fat plant-based diet and regular exercise
Description: Participants will lose \~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
Study NCT02763774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking exercise
Description: Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
Study NCT02763774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stationary cycling exercise
Description: Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
Study NCT02763774 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
Study NCT02308800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantum™ Therapy - NPWT with Prontosan
Description: Negative pressure wound therapy with Prontosan irrigation.
Study NCT02308800 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Quantum™ Therapy
Description: Negative pressure wound therapy without irrigation.
Study NCT03721757 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nivolumab, Surgery, Radiotherapy
Description: A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to radiotherapy commencing. Six further doses of nivolumab will be received post radiotherapy
Study NCT03721757 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Nivolumab, Surgery, Chemoradiotherapy
Description: A single dose of nivolumab 7-14 days before curative surgery. A further single dose will be administered following surgery and prior to Chemoradiotherapy (cisplatin) commencing. Six further doses of nivolumab will be received post radiotherapy
Study NCT03301402 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Air purifier
Description: Air purifier with filter at automatic mode on all time
Study NCT03518359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Stress Resilience Training (ESRT)
Description: ESRT involves six weekly 90-minute group classes and one 2 - 4 hour retreat. Classes focus on developing mindfulness skills (i.e. sustained attention, open monitoring, emotional regulation, meta-cognition) in the context of skills and concepts for managing stress, particularly in practicing medicine. Homework consists of 20 minutes per day of mindfulness exercises following guided meditation CDs or videos of movement-based practice, and practice will be reported periodically by text. A 3-hour outdoor retreat occurs at week six. The central exercises of ESRT are the body scan, sitting meditation, chi gong and yoga. For both arms, the weekly teaching sessions occur on a workday morning during protected time at Parnassus, Mission Bay or Zuckerberg San Francisco General Hospital campus.
Study NCT03518359 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control
Description: Control group participants will meet for 6 weeks, 90 minutes each week, for classes focuses on stress management through rest and exercise, with equivalent protected time and small group bonding but without the use of contemplative practices. Topics will include the history of surgery, patient perspective, the physician personality, technical mastery, fallibility and limits, balancing compassion and detachment and knowing when not to operate. For daily practice, control participants will be asked to devote 20 min per day to stress management through rest and exercise again reported daily by text.
Study NCT01178905 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ultrashort heat inactivation
Study NCT03175497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telatinib Mesylate
Description: Telatinib mesylate tablets will be administrated twice a day orally
Study NCT01232790 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-acetylcysteine 1200mg bid for 3 days
Study NCT01232790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02816294 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Housing Prescription
Study NCT01122498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS+Standard of care or Standard of care
Description: BMP-655/ACS 0.015mg/mL
Study NCT01122498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS+Standard of care or Standard of care
Description: BMP-655/ACS 0.05mg/mL
Study NCT01122498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMP-655/ACS+Standard of care or Standard of care
Description: BMP-655/ACS 0.15mg/mL or 0.025mg/mL
Study NCT01041222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 333611
Description: 5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
Study NCT01041222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ISIS 333611
Description: 5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
Study NCT03592888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mDC3/8-KRAS Vaccine
Description: Mature dendritic cell (mDC3/8) vaccine (primer and booster) in subjects with resected pancreatic adenocarcinoma
Study NCT02988011 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric by-pass surgery
Description: Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
Study NCT02988011 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-caloric diet
Description: Energy restricted diet with a total energy intake of 800-1200kcal/day
Study NCT01161381 — intervention group
Intervention type: DEVICE
Intervention: Estimation of nonlinear indices from Polysomnography
Description: All subjects underwent full night polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) were extracted from three biosignals (airflow from a nasal cannula, thoracic movement and Oxygen saturation) providing input to a data mining application for the creation of predictive models for AHI.
Study NCT04474444 — intervention group
Intervention type: OTHER
Intervention: attendance by ambulance crew
Description: hear, attendance, convey
Study NCT02858453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125 100 mg
Description: Synthetic SHIP1 activator
Study NCT02858453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQX-1125 200 mg
Description: Synthetic SHIP1 activator
Study NCT02858453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Appearance and weight matched placebo tablets
Study NCT05169892 — intervention group
Intervention type: PROCEDURE
Intervention: Aquablation
Description: Aquablation
Study NCT02218606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate 1000 mg po daily
Study NCT02218606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m2 IV
Study NCT02218606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone 5 mg po BID
Study NCT04358770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clocortolone Pivalate
Description: Cream, 0.1%
Study NCT04358770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clocortolone Pivalate
Description: Cream, 0.1%
Study NCT01852318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin 75mg daily for 12 weeks
Description: oral pregabalin 75mg daily for 12 weeks
Study NCT01852318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fexofenadine 60 mg daily for 12 weeks
Description: fexofenadine 60 mg daily for 12 weeks
Study NCT01852318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03663673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: EpiCeram
Description: To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
Study NCT03663673 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Aveeno Daily Moisturising Sheer Hydration Lotion®
Description: To compare skin barrier function, assessed by TEWL AUC, between non-lesional areas of the skin treated with EpiCeram®, Aveeno Daily Moisturising Sheer Hydration Lotion®, and no emollient use over a period of one week.
Study NCT02185222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 100 000 UI
Description: Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
Study NCT02185222 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
Study NCT01253135 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Fibrin
Description: Topical application of fibrinogen spray, followed by thrombin spray
Study NCT01253135 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: White Petrolatum
Description: Topical application
Study NCT01774877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xinfeng capsule
Description: Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
Study NCT01774877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
Study NCT02097953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daptomycin
Study NCT02097953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Study NCT00511810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Fish Oil
Description: Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
Study NCT00511810 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Fish Oil
Description: Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
Study NCT03918811 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive Pressure Extubation Technique
Description: Positive-pressure extubation is performed by only one operator. Ventilator parameters are set to pressure support ventilation mode, with an inspiratory pressure of 15 cm H2O and PEEP of 10 cm H2O. Then, the cuff is deflated, and the ETT is removed without endotracheal suction. Once the ETT is removed, a suction catheter is introduced through the mouth to suction secretions drawn to the oropharynx by the air flow from the ventilator passing between the ETT and the larynx.
Study NCT03918811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Extubation Technique
Description: Traditional extubation is performed by 2 operators. Without reconnection to the ventilator, the closed suction system catheter is introduced by one of the operators into the ETT and suctioning is initiated. The cuff is immediately deflated by the other operator, and the ETT is removed with continuous endotracheal suction during the whole procedure by the first operator.
Study NCT00313846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
Study NCT00313846 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
Study NCT03921736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril
Description: 4 mg/day p.o. for 12 months
Study NCT03921736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: hydrochlorothiazide 25 mg/day p.o. for 12 months
Study NCT03921736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estracomb TTS
Description: Transdermal patches releasing 17β-estradiol (0.05 mg/24 hours) and norethisterone (0.25 mg/24 hours) for 12 months
Study NCT04396652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adductor canal block (ACB) group
Description: Patients will receive ACB under ultrasound guidance in which the adductor canal was identified beneath the sartorius muscle and 20 ml of 0.25% Levobupivacaine will be injected in the canal
Study NCT04396652 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peri-articular injection group
Description: Patients in group II will receive intraoperative peri-articular (cocktail) injection and will be performed by a single surgeon.~A periarticular cocktail injection consisting of 90 mL of normal saline, 17.5 mL of 0.5% levobupivacaine, 2 mL of ketorolac (30 mg), and 0.5mg (0.5mL) of adrenaline, The total volume of the cocktail will be 110 mL
Study NCT01333423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: 40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
Study NCT01333423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seliciclib
Description: Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
Study NCT02154139 — intervention group
Intervention type: DRUG
Intervention: Leuprorelin acetate
Description: Leuprorelin acetate SR 11.25 mg for injection
Study NCT01126216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Cisplatin
Description: Experimental: Paclitaxel (20mg/m\^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m\^2/d) on days 1-4 and 29-32,
Study NCT01126216 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Reduced RT
Description: Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
Study NCT01126216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU/Cisplatin
Description: Active Comparator: 5-Fluorouracil(600mg/m\^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m\^2/d) on days 1-5 and 29-33
Study NCT01126216 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard RT
Description: Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
Study NCT03528148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycling
Description: Active cycling
Study NCT03528148 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Conventional physical therapy
Study NCT03528148 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical therapy
Description: Conventional physical therapy
Study NCT00782197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRGF Intraarticular injection
Description: Three consecutive PRGF injections each one week apart.
Study NCT00782197 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid Intraarticular injection
Description: Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
Study NCT01033500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
Study NCT03565354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iron isomaltoside(Monofer®)
Description: intravenous iron isomaltoside
Study NCT02627560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
Study NCT02627560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: moisten the surgical wound surface with 20 ml placebo (0.9% saline)
Study NCT03257436 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CRT-D
Description: Left Ventricular MultiSite Pacing
Study NCT05387616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Induction therapy will comprise 6 cycles of copanlisib, administered by intravenous Infusion at a dose of 60 mg on day 1,8,15 of cycles 1-6 to be given every 28 days.~Consolidation therapy will comprise another 24 weeks of copanlisib in patients with clinical Remission 28 days after the last induction cycle. It will be administered by intravenous Infusion at a dose of 60 mg on days 1 and 15 of cycles 7 - 12 to be given every 28 days.~Maintenance therapy will comprise another 72 weeks of copanlisib in patients with clinical remissions 28 days after the last consolidation cycle.
Study NCT05387616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction therapy will comprise 6 cycles of obinutuzumab, administered by intravenous infusion at a dose of 1000 mg on days 1,8, 15 of cycle 1 and on day 1 of cycles 2 - 6 to be given every 28 days.~Consolidation therapy will comprise of another 24 weeks of obinutuzumab in patients with clinical remission 28 days after the last induction cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.~Maintenance therapy will comprise another 72 weeks in patients with clinical remission 28 days after the last consolidation cycle. Obinutuzumab will be applied at a dose of 1000 mg by intravenous infusion every 8 weeks.
Study NCT01245101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
Study NCT01245101 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir
Description: Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
Study NCT02280330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MNP group
Description: MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
Study NCT02280330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
Study NCT03971331 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAC catheter and critical care ultrasound examination
Description: Patients in study group were placed the PAC and performed critical care ultrasound(CCUS) to monitor the pathophysiological changes of the lung and the hemodynamics immediately
Study NCT01753882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: Agent + training vs Placebo + training
Study NCT01753882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Agent + training vs Placebo + training
Study NCT03286920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral nutrition supplement
Description: As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
Study NCT03286920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Tube feeding nutrition supplement
Description: As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
Study NCT01616043 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Glyaderm
Description: acellular dermis
Study NCT01616043 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: STSG
Description: autologous split skin only